|  |  |  | | | | | PR Newswire: Clinical Trials & Medical Discoveries | | | | | | | | | | | | | | | | | | | Conference Call on Thursday, November 4, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and nine months ended Septe | | | | | | | | | | | | | | | | | | | | | | | | | SANTIAGO, Chile, Nov. 4, 2010 /PRNewswire/ -- MediVet South America has introduced a major scientific advancement in animal stem cell regenerative therapy for dogs, cats and horses suffering from osteoarthritis, hip dysplasia, ligament and cartilage injuries, and degenerative diseases. The procedure | | | | | | | | | | | | | | | | | | | | | | | | | COLUMBIA, Md., Nov. 4, 2010 /PRNewswire/ -- The Memory Improvement with Docosahexaenoic acid (DHA) Study (MIDAS) published online in March 2010 and in the November print issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in | | | | | | | | | | | | | | | | | | | | | | | | | Twenty percent fewer lung cancer deaths seen among those screened with CT than with chest X-ray in a trial conducted by the American College of Radiology Imaging Network and the Lung Screening Study group. PHILADELPHIA, Nov. 4, 2010 /PRNewswire-USNewswire/ -- The National Cancer Institute (NCI) rele | | | | | | | | | | | | | | | | | | | | | | | | | Recently Released Lung Screening Trial Data Confirms Mortality Benefit WASHINGTON, Nov. 4, 2010 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) hailed today's announcement by the National Cancer Institute (NCI) on the National Lung Cancer Screening Trial (NLST) as a seminal moment for the lung | | | | | | | | | | | | | | | | | | | | | | | | | For patients with tendinopathy both surgical and nonsurgical treatments show promise, need more study ROSEMONT, Ill., Nov. 4, 2010 /PRNewswire-USNewswire/ -- The following was released today by the American Academy of Orthopaedic Surgeons: Synopsis: A patient with a long head biceps (LHB) tendinopat | | | | | | | | | | | | | | | | | | | | | | | | | COLD SPRING HARBOR, N.Y., Nov. 4, 2010 /PRNewswire/ -- AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant | | | | | | | | | | | | | | | | | | | | | | | | | MADISON, Wis., Nov. 4, 2010 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI) announced today that it has been awarded a total of $977,915 for investments in four qualifying therapeutic discovery projects. CDI, the world's largest producer of human tissue cells for drug discovery and | | | | | | | | | | | | | | | | | | | | | | | | | PISGAH FOREST, N.C., Nov. 4, 2010 /PRNewswire/ -- Pisgah Labs, Inc. (http://www.pisgahlabs.com), an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant. The Qualifying Therapeutic Discovery Project Program (http:/ | | | | | | | | | | | | | | | | | | | | | | | | | CAMBRIDGE, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of VPRIV® (velaglucerase alfa for injecti | | | | | | | | | | | | | | | | | | | | | | | | | ANN ARBOR, Mich., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTD | | | | | | | | | | | | | | | | | | | | | | | | | BETHESDA, Md., Nov. 4, 2010 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants. | | | | | | | | | | | | | | | | | | | | | | | | | LYON, Francia, 4 de noviembre de 2010 /PRNewswire/ -- Sanofi Pasteur, la división de vacunas del Grupo sanofi-aventis (EURONEXT: SAN y NYSE: SNY), anunció hoy que su vacuna contra el dengue ya está cursando la fase final de desarrollo. La vacuna contra el dengue de Sanofi Pasteur, que | | | | | | | | | | | | | | | | | | | | | | | | | LYON, France, November 4, 2010 /PRNewswire-FirstCall/ -- - First Phase 3 Study Underway in Australia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pa | | | | | | | | | | | | | | | | | | | | | | | | | EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated w | | | | | | | | | | | | | | | | | | | | | | | | | Studies Highlight Concord Grape Juice as Beneficial to Heart Health and Possibly More CONCORD, Mass., Nov. 3, 2010 /PRNewswire-USNewswire/ -- More than 50% of Americans list heart health as their number one health concern.(1) According to recent scientific papers published in Nutrition Reviews(2) an | | | | | | | | | | | | | | | | | | | | | | | | | LYNBROOK, N.Y., Nov. 3, 2010 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC) (the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Pro | | | | | | | | | | | | | | | | | | | | | | | | | NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million. The | | | | | | | | | | | | | | | | | | | | | | | | | GAITHERSBURG, Md., Nov. 3, 2010 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and | | | | | | | | | | | | | | | | | | | | | | | | | ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ -- STB Lifesaving Technologies® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479. The Qualifying Therapeutic Discovery Project was included in the | | | | | | | | | | | | | | | | | | | | | | | | | BASKING RIDGE, N.J., Nov. 3, 2010 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at IMPACT 2010 held a | | | | | | | | | | | | | | | | | | | | | | | | | BASKING RIDGE, N.J., Nov. 3, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying T | | | | | | | | | | | | | | | | | | | | | | | | | TORONTO, Nov. 3, 2010 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasin | | | | | | | | | | | | | | | | | | | | | | | | | BEIJING, Nov. 3, 2010 /PRNewswire-Asia/ -- "For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li. "This is a new hope for cancer pa | | | | | | | | | | | | | | | | | | | | | | | | |  CHICAGO, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today ann
| | | | | | | | | | | | | | | | | | | | | | | | | DALLAS and NEW YORK, Nov. 3, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has commen | | | | | | | | | | | | | | | | | | | | | | | | | SEATTLE, Nov. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chemotherapeutic agent docetaxel. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidyli | | | | | | | | | | | | | | | | | | | | | | | | | LANGHORNE, Pennsylvania and OXFORD, England, November 3, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (caprom | | | | | | | | | | | | | | | | | | | | | | | | | WAYNE, Pa., Nov. 3, 2010 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has been awarded a $244,500 federal Therapeutic Discovery Project grant. | | | | | | | | | | | | | | | | | | | | | | | | | CHAPEL HILL, N.C., Nov. 3, 2010 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstra | | | | | | | | | | | | | | | | | | | | | | | | | CAMBRIDGE, Mass., Nov. 3, 2010 /PRNewswire/ -- The DNA Medicine Institute, a biomedical research organization whose mission is to advance patient care, alleviate human suffering, and treat disease through innovation, has received a $222,999 grant from the U.S. government under the Qualifying Therape | | | | | | | | | | | | | | | | | | | | | | | | | CLEVELAND, Nov. 3, 2010 /PRNewswire/ -- From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases. The list of breakthrough | | | | | | | | | |  | |  | |  |
No comments:
Post a Comment